LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Inotek senior management, including David P. Southwell, President and Chief Executive Officer, William K. McVicar, Ph.D., Executive Vice President, Chief Scientific Officer, and Claudine Prowse, Ph.D., Vice President, Strategy and Investor Relations Officer, will participate in a fireside chat discussion at the Piper Jaffray 27th Annual Healthcare Conference on December 2, 2015, at 12:00 p.m. Eastern Time at The New York Palace, in New York, NY.
